Please login to the form below
Memorial Sloan Kettering
This page shows the latest Memorial Sloan Kettering news and features for those working in and with pharma, biotech and healthcare.
FDA begins speedy review of BMS’ CAR-T liso-cel
The lawsuit argued that Gilead subsidiary Kite Therapeutics infringed on a patent licensed by BMS’ Juno Therapeutics from Sloan Kettering and Memorial Sloan Kettering Cancer Centre for exclusive rights to its ... BMS alleged that Kite scientists copied
Latest news
-
US start-up EQRx promises approach that will slash drug prices
EQRx is co-founded by Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center whose academic interests focus on pricing as well as
-
Gilead owes BMS millions after losing Yescarta patent infringement trial
Memorial Sloan Kettering Cancer Center for the exclusive rights to the technology. ... We remain steadfast in our opinion that Sloan Kettering's patent is not infringed and is invalid," it said.
-
Rival Novartis, Merck drugs square up on rare lung cancer at ASCO
Tepotinib also seemed to work in patients with brain metastases who “benefitted equally” from treatment, according to lead investigator Paul Paik of Memorial Sloan Kettering Cancer Centre in the US.
-
AZ’s Sean Bohen to exit after business overhaul; report
Last week’s business reshuffle also saw Memorial Sloan Kettering Cancer Center physician José Baselga brought in to head the company’s cancer R&D unit – a somewhat controversial choice given
-
AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
Dr José Baselga. Dr Baselga – formerly chief medical officer at Memorial Sloan Kettering Cancer Centre – becoming head of cancer R&D.
More from news
Approximately 1 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
Encouraging signs in biomarker R&D
He also cited an FDA-approved TMB test developed by Foundation Medicine and Memorial Sloan Kettering Cancer Center as an example.
-
Deal Watch September 2016
No other financial details were disclosed. Fate Therapeutics entered a three year arrangement with Memorial Sloan Kettering Cancer Center to use engineered pluripotent cell lines to develop T cell product candidates.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Lilly appoints Maura Dickler as VP of late phase oncology development
She will join the pharma firm from the Memorial Sloan Kettering Cancer Center. ... She will move to the pharmaceutical company from the prestigious Memorial Sloan Kettering Cancer Center, where she currently serves as associate member, Breast Medicine
-
José Baselga joins BMS’ board of directors
Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and
-
OncoMed’s CMO steps down
Prior to this, Dr Dupont was director of early and late stage development at Genentech, and served as a researcher in tumour immunology at the Memorial Sloan Kettering Cancer Center.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Getting personal with wearable tech
In July 2016, a prestigious US cancer centre, The Memorial Sloan Kettering Cancer Center (MSK), announced their plans to evaluate wearables and other mobile technology to assess cancer patients' quality of
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Roche’s Ocrevus boasts positive long-term data in MS
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
